What Happened?
Cambridge, MA-based Anokion Appointed Anthony Rossomando as Vice President of Technical Operations
About the Company
Anokion, a spin-off from the Ecole Polytechnique Fédérale de Lausanne (EPFL), is focused on applying the company`s antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and to treat autoimmune and allergic diseases. As a platform technology, Anokion`s approach to antigen-specific tolerance can be translated to virtually any protein in numerous clinical indications.
About the Person
Anthony Rossomando is Chief Technology Officer at NeuBase Therapeutics. Previously, Anthony held various senior IT leadership roles in the industry.
Info Source
News
Short Profile